{"name":"Xenon Pharmaceuticals","slug":"xenon","ticker":"XENE","exchange":"NASDAQ","domain":"xenon-pharma.com","description":"Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression. In addition, the company's Phase 1 Single Ascending Dose/Multiple Ascending Dose products include XEN1701 targeting the sodium channel and XEN1120 targeting the Kv7 potassium channel for the treatment of pain. The company has a license and collaboration agreement with Neurocrine Biosciences, Inc. for the development of NBI-921355, a Nav1.2/1.6 sodium channel inhibitor that is in Phase 1 clinical trials for the treatment of certain types of epilepsy. ","hq":"Burnaby, BC, Canada","founded":0,"employees":"358","ceo":"Ian Bhatt","sector":"CNS / Epilepsy","stockPrice":57.08,"stockChange":-0.57,"stockChangePercent":-0.99,"marketCap":"$5.4B","metrics":{"revenue":50000000,"revenueGrowth":1843.8,"grossMargin":0,"rdSpend":300938000,"netIncome":-345910000,"cash":548886016,"dividendYield":0,"peRatio":-12.1,"fiscalYear":"FY2017"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2034-06-01","label":"XEN901 patent cliff ($0.0B at risk)","drug":"XEN901","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":2,"colorKey":"oncology","drugs":[{"name":"XEN1101","genericName":"XEN1101","slug":"xen1101","indication":"Treatment of trigeminal neuralgia","status":"phase_3"},{"name":"14C-XEN1101","genericName":"14C-XEN1101","slug":"14c-xen1101","indication":"Other","status":"phase_1"}]}],"pipeline":[{"name":"XEN1101","genericName":"XEN1101","slug":"xen1101","phase":"phase_3","mechanism":"XEN1101 is a selective Nav1.7 sodium channel blocker.","indications":["Treatment of trigeminal neuralgia"],"catalyst":""},{"name":"14C-XEN1101","genericName":"14C-XEN1101","slug":"14c-xen1101","phase":"phase_1","mechanism":"Small molecule","indications":[],"catalyst":""}],"recentEvents":[{"date":"2024-02-27","type":"earnings","headline":"Xenon Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results","summary":"Xenon Pharmaceuticals reported its fourth quarter and full year 2023 financial results, which included revenue of $13.4 million and a net loss of $44.1 million.","drugName":"","sentiment":"neutral"},{"date":"2023-11-14","type":"deal","headline":"Xenon Pharmaceuticals Announces Collaboration with University of California, San Francisco to Develop Novel Therapeutics for Neurological Disorders","summary":"Xenon Pharmaceuticals announced a collaboration with the University of California, San Francisco to develop novel therapeutics for neurological disorders, including epilepsy and Parkinson's disease.","drugName":"","sentiment":"positive"},{"date":"2023-08-07","type":"trial","headline":"Xenon Pharmaceuticals Announces Positive Topline Results from Phase 2 Clinical Trial of XEN901 in Patients with Focal Seizures","summary":"Xenon Pharmaceuticals announced positive topline results from a Phase 2 clinical trial of XEN901 in patients with focal seizures, which showed a significant reduction in seizure frequency.","drugName":"","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPalF4RnBqQlU5MEp5MWtma21jdnN5ZFJNZ0tMUmtScTF6VEtDXzJGQ0kxbHdNT1dmSHlNczlnMHoyVjNSV2hGMWNPMjVqbF84cktDcnJPRElmdVluQXdaQkZqOU4yekhqRmlmVFZUeVBVMHJjZExHVUY1aEJmamtlTnhiT1ZGeGl3bVlpekNWckxJcmt5NF9jUmVGQk15S0ZlbUtLMGNqZWktaGY1NlY3Y2VVa1ZUNGY1eDFodmhURUVHNzNKMFNucXdkNEMybVZOM2VKM2VWTFpDUQ?oc=5","date":"2026-03-27","type":"pipeline","source":"The Motley Fool","summary":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know - The Motley Fool","headline":"Xenon Pharma Stock Up 55% as Insider Sells $78K in Shares. Here's What Investors Should Know","sentiment":"neutral"},{"date":"2026-03-13","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"date":"2026-03-12","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxOWjFPVUI3R1pOSWMxUHM4aHRvUUZkV3U5b05UbHZSZ3ljdGNjNjBxYXhiQklNTHlKM3FfMEN6dGRmMUJOT2R2UlJYTFZRZTZLOC1YT2xzOWNDWEdzZ0tEWkxTN3NFTktSV19oTHRLVFlTTnVSSWs0cXlOQk1QekVzSmg0LVhvNnZ0bzd0LVVmbDRwX2M0a2hrMHUydEhGcWY2bHVWbFVMeGp0eUpkX1A4SXJMZjVRbmpORTVJ?oc=5","date":"2026-03-10","type":"pipeline","source":"Stock Titan","summary":"Biotech Xenon raises $650M in stock sale at $57 a share - Stock Titan","headline":"Biotech Xenon raises $650M in stock sale at $57 a share","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitwFBVV95cUxNTEpRb0VYNnpjWTBpNUlrcnhmR0QxVllqaVJVakNrcjZheTIxQmRISURiUk1ONzBKeFhoWGRvUkRSREhzTEw2RF96WTQ4bGZFZXlabWpUdmRzcEJXb0p2b1o4MVdaUGVEeDB0Mi1DNzJfdW9XVXNlMDBIZXg3YlFhN3E2cWJ3TmoyanBlU3A3cno3YUtTNWNxSlQ5bWh4M1N1YVdadnNMRk05MVluQk5CQ3lhNFU3TFU?oc=5","date":"2026-03-09","type":"pipeline","source":"The Globe and Mail","summary":"Xenon stock soars as B.C. drug developer reports strong results for epilepsy treatment - The Globe and Mail","headline":"Xenon stock soars as B.C. drug developer reports strong results for epilepsy treatment","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxOc3NrcEx6RUMxdUw3UFNLR2pVRnEydmlOV2hYLVVwM0paRFFnY21EQ1JEMm1UQVRjUXFqVW5udkRza0tJUFJpZVZMblhiVGU2X0pRNndjVGMzSEU4cnBEbGVyUWZWanpZeEVHbWRsVGF5c2ExSFhLX3JHbnhqNHlVMkg1Y0VYOTdNMlVDbDZWNm5kaEMtS0FfUElJd3BVUV9tNUUxQQ?oc=5","date":"2026-03-09","type":"pipeline","source":"Stock Titan","summary":"$500M stock sale: neuroscience drug maker Xenon tests market appetite - Stock Titan","headline":"$500M stock sale: neuroscience drug maker Xenon tests market appetite","sentiment":"neutral"},{"date":"2026-03-09","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAJBVV95cUxQZ2tFRmVWUFRZS3ltVTg2cnVxTjIwRHBmVTdzeEhkdHdpVUtzN0VENGpVZXpQV0RwcU1jdVVORjRUVHhmcWkwMWZ2YUJXN2VtdVktSXVCVGZhRkNCZ0lXVVFkMlFqSG5nOHJFZ1RLUDBqc2ZKb01NeTh0cTh3OWdzYjhuTUJXWmFoYzJyc1VlRGN0UEwwd1pZNG9qUl9QeGxzQ25SU2dKdHBleXVFSVkxOTBvRGdYbkZydzRnMDJNMmFyRlVNcVE5RW9EdFp1V1pTczVrbmVmREN2MWNHamFMUUNDS1JvZXdvY2E1eWxYYkM3aVFfVHZGVjFIcE41aGQyaDE4MTl0eHpwY2lCNm5SOFg3aHgwckgwVDJmdFFqRTRieUpH?oc=5","date":"2026-03-08","type":"trial","source":"globenewswire.com","summary":"Xenon to Announce Topline Results from Phase 3 X-TOLE2 - globenewswire.com","headline":"Xenon to Announce Topline Results from Phase 3 X-TOLE2","sentiment":"neutral"},{"date":"2026-02-27","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxNcUVOR3ZnYlFUQVJnNjBGYmx6Z3FOellXY2Vucnh2Q20xZmlPeF82X0Ezc2xPTnZqUmVaRXBad1kwOHlnREt5VWlwa3ZxM1JmaGtrMmIwTlhBX1NlZ00xVW8xSjFWdndnZzlxYVBBMksxRXRFUmlSSnBGSGFFYnM3NUJ0LVRjVFZPYWN6bw?oc=5","date":"2026-02-24","type":"pipeline","source":"Investor's Business Daily","summary":"Xenon Pharmaceuticals Stock Scores RS Rating Upgrade - Investor's Business Daily","headline":"Xenon Pharmaceuticals Stock Scores RS Rating Upgrade - Investor's Business Daily","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimAFBVV95cUxOa3FoeGRUM1NVd0RWTTA5VlpsVzFZbVVQZEYtTS00YWliekF0U0R5V2pKOUtpS0FiaHJYdFpfdFZKWEg0YkIxX2xxM2Zva280R3IwVFZBNF9XS1Z3ZTBDNjBpcUl4Vzk1UWxSNXBjN2FiSVVRLWtHQzh0NUh6Y0tUY0J1TDI0WWh2WnhldWJaLVFDamtsS2ZPYw?oc=5","date":"2026-02-12","type":"trial","source":"RTTNews","summary":"Xenon Pharma To Report Epilepsy Trial Results Next Month - RTTNews","headline":"Xenon Pharma To Report Epilepsy Trial Results Next Month","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi0AFBVV95cUxNNmlpaWlZUkkzcHQ0Y0RQc2lTdFZPVkM3MmNlUzVzX21RWmoxaTlWbGRkQnE2Z1B6dWRPazQ4RUktOXNjUzI1aVdDX3N1bW1ubWpramRXREVXMmZacVkxWk9kV0JBaS1rSnBTOXhGUllKU1lJZUttcEpUVXRZRTl5MVYwTjBhR0Fwb2Q1bEI3ckt4WXBsbUJsZXNkVlM4U0RDLWg4LWMzVHVqcE5tQ1V3VjZ0cURjRmdzbFhiN2xNNFNBS0tVYWd1ckNaQ3gwaXhY?oc=5","date":"2026-01-05","type":"pipeline","source":"Quiver Quantitative","summary":"Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026 - Quiver Quantitative","headline":"Xenon Pharmaceuticals Inc. to Present at 44th Annual J.P. Morgan Healthcare Conference in January 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiuwFBVV95cUxQdWFjSms4YllueTRzeGVIUnM5anp4N0dDNVRJbU9aSTFNb21uVEpTc19jRTJyYTRrLVVPNXNfcGwzdTlfWTBtV3c3SUFncFZraXpwX3FaSU9pTi1QdFB4VktTeWlab1MzTnBpeGFaNVgzYktSR05hUHFQeHI5dWtkS2JpY1Zob3VyeEYwMXlmdXlwUkpMenlhaE9CVGRDaWd5eC02TWQ2cXVNWU85bHR6SS1ENXFUYjJmLTZz?oc=5","date":"2025-12-18","type":"trial","source":"Seeking Alpha","summary":"Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE) - Seeking Alpha","headline":"Xenon Pharmaceuticals: Derisked Pipeline Ahead Of Critical 2026 Phase 3 Readout (NASDAQ:XENE)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMilAFBVV95cUxQd1VYc21vSTU5SGFsNkV3RnNGS29TSjd6QlZiMFdZYVhiTXpaWkVTU1hRSnhoZ1hTNU9HSm5OSDhlR25rNWJ1S1lhOVV3UWZ3b2VXN2Y1RjAyTUNtT0JGSGNMLUZaYW10YWl3YVdieXU3NVNlamkyUEVqYnh1ZlB0TG0xMGtrMlh0WXlSamdOVlJwWWZ0?oc=5","date":"2025-12-07","type":"trial","source":"Yahoo Finance","summary":"Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data? - Yahoo Finance","headline":"Is Xenon Pharmaceuticals (XENE) Quietly Reframing Its Epilepsy Bet Through Equity Awards and New Data?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgFBVV95cUxOdHBseTJ5ZTVZQTFUcjJDVDd1MTRrZ3o0S2xkdGNoQ2t6YzZnWmt5d2dNXzZ5ZHJKdV90cGlnalg1M1BnWFBVMDlRX2xNRll0Zmw1ck5ZZFhsQWlpZVdfLVF5LUNLOHJDRDVmbHMyekVyNUpETFRMU2ppMnhyOFB3ZzVRU2I5VU10RHhIVVJyY2xGaHNaVWlNeThBRENLeXpHRmc2cFVLUEVvSG1rcEFqTlJiZVZvNGpta2xJSEZjWi1TbV9VYVV4TS1uMWR6dw?oc=5","date":"2025-08-12","type":"trial","source":"Seeking Alpha","summary":"Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release - Seeking Alpha","headline":"Xenon Pharmaceuticals: Pushing Azetukalner Towards Finish Line With Phase 3 2026 Data Release","sentiment":"neutral"}],"patents":[{"drugName":"XEN901","drugSlug":"gaba_a-receptor-modulator","patentNumber":"","type":"Patent Cliff","expiryDate":"2034-06-01","territory":"US","annualRevenue":0}],"drugCount":2,"phaseCounts":{"phase_3":1,"phase_1":1},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":["Ultragenyx Pharmaceutical Inc.","GW Pharmaceuticals plc","Zogenix, Inc."],"therapeuticFocus":["Epilepsy","Neurological Disorders"],"financials":{"source":"sec_edgar+yahoo","revenue":311000,"revenuePeriod":"2017-12-31","revenueHistory":[{"value":311000,"period":"2017-12-31"},{"value":16000,"period":"2017-12-31"},{"value":264000,"period":"2017-09-30"},{"value":15000,"period":"2017-06-30"},{"value":16000,"period":"2017-03-31"}],"grossProfit":null,"grossProfitHistory":[],"rdSpend":300938000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-345910000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":null,"cashHistory":[],"totalAssets":633163000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":358,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":57.08,"previousClose":57.65,"fiftyTwoWeekHigh":63.95,"fiftyTwoWeekLow":26.74,"fiftyTwoWeekRange":"26.74 - 63.95","fiftyDayAverage":47.99,"twoHundredDayAverage":40.89,"beta":0.74,"enterpriseValue":4254979840,"forwardPE":-12.1,"priceToBook":7.85,"priceToSales":726.2,"enterpriseToRevenue":567.33,"enterpriseToEbitda":-11.48,"pegRatio":0,"ebitda":-370527008,"ebitdaMargin":0,"freeCashflow":-175082752,"operatingCashflow":-279118016,"totalDebt":7944000,"debtToEquity":1.4,"currentRatio":13.41,"returnOnAssets":-32.6,"returnOnEquity":-51.8,"analystRating":"1.1 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":19,"targetMeanPrice":79.24,"targetHighPrice":100,"targetLowPrice":58.58,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":0.1,"institutionHeldPercent":95.3,"sharesOutstanding":95427159,"floatShares":78362782,"sharesShort":5451476,"shortRatio":2.59,"shortPercentOfFloat":5.7,"epsTrailing":-4.36,"epsForward":-4.73,"revenuePerShare":0.1,"bookValue":7.27,"officers":[{"age":49,"name":"Mr. Ian C. Mortimer C.M.A., CPA, M.B.A.","title":"President, CEO, Principal Accounting Officer & Director"},{"age":57,"name":"Ms. Andrea  DiFabio J.D.","title":"Chief Legal Officer & Corporate Secretary"},{"age":53,"name":"Dr. Christopher John Kenney M.D.","title":"Chief Medical Officer"},{"age":54,"name":"Mr. Thomas Patrick Kelly J.D.","title":"Chief Financial Officer"},{"age":52,"name":"Dr. Matthew D. Ronsheim Ph.D.","title":"Chief Operating Officer"},{"age":65,"name":"Ms. Shelley  McClCoskey B.A.","title":"Executive Vice President of Human Resources"},{"age":64,"name":"Dr. Robin P. Sherrington Ph.D.","title":"Executive Vice President of Strategy & Innovation"},{"age":64,"name":"Dr. James R. Empfield Ph.D.","title":"Executive Vice President of Drug Discovery"}],"industry":"Biotechnology","irWebsite":"","website":"https://www.xenon-pharma.com","phone":"604 484 3300"}}